TABLE 4

Changes between baseline and 3 months in the troglitazone nonresponders and responders

Non-responders*RespondersP
n3573
Fasting glucose (mg/dl)−1.0 (−26.0, 50.0)−4.0 (−26.0, 10.0)0.008
Kg (min−1/100)−0.01 (−0.53, 0.75)0.06 (−1.69, 1.75)0.12
SI (min−1 per μU/ml × 10−4)−0.09 (−2.13, 0.44)1.41 (0.54, 7.67)<0.000
Total insulin area (μU/ml × min)−287 (−7,517, 4,487)−2,717 (−19,364, 985)<0.000
AIRg (μU/ml × min)18 (−769, 341)−15 (−926, 364)0.04
DI−6 (−1,010, 625)477 (−1,822, 2,732)<0.000
Pill compliance (% of prescribed)§87 (20, 100)90 (46, 99)0.78
  • Data are median (minimum, maximum). P values for difference between groups, by Wilcoxon’s rank-sum test.

  • *

    * Tertile 1 for change in SI, Table 3;

  • tertiles 2 and 3 for change in SI, Table 3;

  • P < 0.01 for change from baseline within a group by Wilcoxon’s signed-rank test;

  • §

    § during first 3 months on trial.